Ardelyx

Ardelyx products

 IBSRELA (tenapanor)

Indication: Treatment of irritable bowel syndrome with constipation (IBS-C) in adults
Status: FDA-approved in the U.S.; also marketed in Canada

XPHOZAH (tenapanor)
Indication: Reduction of serum phosphate in adults with chronic kidney disease (CKD) on dialysis, as add-on therapy for patients intolerant or unresponsive to phosphate binders
Status: FDA-approved in the U.S.

PHOZEVEL (tenapanor)
Indication: Hyperphosphatemia in CKD patients on dialysis
Status: Approved and launched in Japan

Wan Ti Le (tenapanor)
Indication: Hyperphosphatemia management in adult dialysis patients
Status: Approved in China; marketed under this local brand name via licensing partner